ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO375

Residual Kidney Function and Sudden Cardiac Death Among Incident Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Okazaki, Masaki, University of California Irvine, Irvine, United States
  • Obi, Yoshitsugu, The University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Shafi, Tariq, The University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Rhee, Connie, University of California Irvine, Irvine, California, United States
  • Kalantar-Zadeh, Kamyar, University of California Irvine, Irvine, California, United States

The survival benefit of residual kidney function (RKF) in hemodialysis patients is likely tied to advantages in fluid and electrolyte management. However, data have been lacking on the relationship between the RKF and sudden cardiac death (SCD). We therefore conducted a nationally representative cohort study to examine the association of RKF with SCD in patients initiating thrice-weekly in-center hemodialysis.


We analyzed a longitudinal data from a retrospective cohort study examining incident dialysis patients at a facility operated by a large dialysis organization in the U.S. from 2007 to 2011.
The predictor was RKF measured by renal urea clearance (CLurea) at baseline and 6 months after initiating hemodialysis. Multivariable cause-specific proportional hazards models were fitted for primary analysis, and restricted cubic splines were fitted for secondary analysis for change in RKF to estimate SCD mortality.


Baseline cohort of 39,749 patients were categorized into five groups according to baseline renal CLurea (<1.5, 1.5 to <3.0, 3.0 to <4.5, 4.5 to <6.0, and ≥6.0 mL/min/1.73 m2). The mean age was 61.6 years, and the median baseline renal CLurea was 3.1 mL/min/1.73 m2. Among a total of 7,737 all-cause deaths, 1,909 SCDs (24.7%) with the incidence rate of 34.0 per 1,000 person-years were observed. Compared with patients who had baseline renal CLurea of >6.0, those of <1.5 was associated with higher risk of SCD: case-mix adjusted hazard ratio was 1.47 (95% CI, 1.27–1.73). Of 12,169 patients with available data on change in renal CLurea, a decline in renal CLurea during the first 6 months of hemodialysis also showed a gradient association with increased SCD mortality.


Lower RKF and loss of RKF were associated with higher SCD mortality in patients starting thrice-weekly in-center hemodialysis.